Videos

Clinical Approach for Unresectable Locally Advanced NSCLC

Vivek Subbiah, MD, associate medical director, Clinical Center for Targeted Therapy, assistant professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses targeting <em>RET </em>alterations in solid tumors during the 2018 AACR Annual Meeting.

Jacqueline C. Barrientos, MD, associate professor of the Karches Center for Oncology Research at the Feinstein Institute for Medical Research, discusses which types of patients with chronic lymphocytic leukemia are the best candidates for treatment with ibrutinib

Martin H. Voss, MD, an assistant attending at Memorial Sloan Kettering Cancer Center, discusses recent data supporting the use of neoadjuvant therapy in patients with locally advanced kidney cancer.

EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases

EGFR+ NSCLC

Jennifer Litton, MD, associate professor in the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses her opinion on the use of PARP inhibitors in the field of breast cancer.&nbsp;

Non-Driver NSCLC: Practice Considerations

Ghassan K. Abou-Alfa, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses results of the CELESTIAL trial. The results were clinically and statistically significant, Abou-Alfa notes.&nbsp;